Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
Erasca, Inc. (ERAS)
Company Research
Source: GlobeNewswire
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation Initial Phase 1 monotherapy data for ERAS-0015 (potential best-in-class pan-RAS molecular glue) planned for H1 2026 and for ERAS-4001 (potential first-in-class pan-KRAS inhibitor) planned for H2 2026 SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced meaningful clinical progress for its RAS-targeting franchise and 2026-2027 milestones. “With both ERAS-0015 and ERAS-4001 INDs previously cleared in May 2025, Erasca’s strong operational execution continues to result in rapid clinical advancement of our RAS-targeting franchise. Notably, ERAS-0015 is
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike [Yahoo! Finance]Yahoo! Finance
- Erasca (NASDAQ:ERAS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Climbs to 3-Year High as Analyst Hikes PT by 83% [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Is Up 60.7% After Early ERAS-0015 Data Highlights Pan-RAS Franchise Ambitions [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 1/15/26 - Form 144
- 1/14/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- ERAS's page on the SEC website